Free tool
FAERS Monitor: Gablofen
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022462 or its brand name (Gablofen, Baclofen). Reports on generic versions are filed under their own applications.
Reports
3,114
Serious
1,575
51% of reports
Hospitalization
807
Death reported
121
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- muscle spasticity771
- withdrawal syndrome421
- device issue376
- drug ineffective294
- drug withdrawal syndrome272
- overdose172
- implant site infection166
- infection164
- hypertonia158
- pruritus157
- device failure154
- device malfunction151
- muscle spasms148
- implant site extravasation125
- pain124
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 3 |
| 2012 | 15 |
| 2013 | 333 |
| 2014 | 243 |
| 2015 | 318 |
| 2016 | 145 |
| 2017 | 139 |
| 2018 | 684 |
| 2019 | 42 |
| 2020 | 247 |
| 2021 | 203 |
| 2022 | 269 |
| 2023 | 170 |
| 2024 | 120 |
| 2025 | 121 |
| 2026 | 62 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,045 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| implant site extravasationSignal | 125 | 1278.4 | 1059.4 | 133,108 |
| implant site infectionSignal | 166 | 519.0 | 445.0 | 79,238 |
| muscle spasticitySignal | 771 | 452.0 | 424.0 | 324,951 |
| hypertoniaSignal | 158 | 191.6 | 164.2 | 28,958 |
| device failureSignal | 154 | 69.0 | 59.1 | 10,157 |
| withdrawal syndromeSignal | 421 | 68.4 | 62.5 | 27,666 |
| device issueSignal | 376 | 28.4 | 25.9 | 9,925 |
| drug withdrawal syndromeSignal | 272 | 21.0 | 18.7 | 5,166 |
| device malfunctionSignal | 151 | 14.5 | 12.4 | 1,893 |
| infectionSignal | 164 | 7.7 | 6.6 | 949 |
| muscle spasmsSignal | 148 | 5.5 | 4.7 | 538 |
| overdoseSignal | 172 | 5.4 | 4.7 | 616 |
| pruritusSignal | 157 | 2.8 | 2.4 | 178 |
| drug ineffective | 294 | 1.5 | 1.4 | 53 |
| pain | 124 | 1.4 | 1.1 | 12 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.